Hoth Therapeutics Inc.

1.48-0.1002-6.34%Vol 467.79K1Y Perf -51.72%
Apr 19th, 2021 11:48 DELAYED
BID1.47 ASK1.49
Open1.56 Previous Close1.58
Pre-Market- After-Market-
 - -%  - -
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
562.25 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap33.71M 
Earnings Rating
Neutral
Price Range Ratio 52W %
0.57 
Earnings Date
12th May 2021

Today's Price Range

1.461.60

52W Range

1.464.96

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-11.24%
1 Month
-27.52%
3 Months
-28.18%
6 Months
-11.73%
1 Year
-51.72%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
HOTH1.48-0.1002-6.34
AAPL134.360.20000.15
GOOG2 298.250.49000.02
MSFT259.28-1.4600-0.56
XOM56.26-0.4000-0.71
WFC44.060.22000.50
JNJ162.550.31000.19
FB302.97-3.2100-1.05
GE13.34-0.0500-0.37
JPM153.00-0.3000-0.20
Earnings HistoryEstimateReportedSurprise %
Q02 2020-0.14-0.20-42.86
Q01 2020-0.17-0.18-5.88
Q03 2019-0.10-0.17-70.00
Q02 2019--0.13-
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.600.00-
3/2021 QR-0.10--
6/2021 QR-0.14--
12/2021 FY-0.39--
Next Report Date12th May 2021
Estimated EPS Next Report-0.10
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume467.79K
Shares Outstanding22.78M
Trades Count1.42K
Dollar Volume8.21M
Avg. Volume3.61M
Avg. Weekly Volume1.46M
Avg. Monthly Volume5.39M
Avg. Quarterly Volume3.79M

Hoth Therapeutics Inc. (NASDAQ: HOTH) stock closed at 1.58 per share at the end of the most recent trading day (a -3.66% change compared to the prior day closing price) with a volume of 1.20M shares and market capitalization of 33.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2 people. Hoth Therapeutics Inc. CEO is Robb Knie.

The one-year performance of Hoth Therapeutics Inc. stock is -51.72%, while year-to-date (YTD) performance is -33.33%. HOTH stock has a five-year performance of %. Its 52-week range is between 1.46 and 4.96, which gives HOTH stock a 52-week price range ratio of 0.57%

Hoth Therapeutics Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 9.39, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -178.19%, a ROC of -213.75% and a ROE of -204.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Hoth Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. Hoth Therapeutics Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Hoth Therapeutics Inc. is Strong Buy (1), with a target price of $10, which is +562.25% compared to the current price. The earnings rating for Hoth Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Hoth Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Hoth Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.43, ATR14 : 0.26, CCI20 : -138.80, Chaikin Money Flow : -0.52, MACD : -0.19, Money Flow Index : 15.26, ROC : -16.40, RSI : 36.43, STOCH (14,3) : 10.77, STOCH RSI : 0.00, UO : 31.77, Williams %R : -89.23), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Hoth Therapeutics Inc. in the last 12-months were: Anthony Hayes (Sold 800 000 shares of value $1 000 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

CEO: Robb Knie

Telephone: +1 646 756-2997

Address: 1 Rockefeller Plaza, New York 10020, NY, US

Number of employees: 2

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

64%36%

Bearish Bullish

56%44%

News

Stocktwits